Bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24037511.
- Also identified by DOI 10.1007/s00590-013-1293-z.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bisphosphonate represents a well-established treatment option in the management of metastatic bone disease and bone loss/osteoporosis in women with breast cancer. These drugs reduce osteoclast. Some bisphosphonate also have osteoblastic function leading to a reducted bone turnover and thereby skeletal-related events. The aim of this review is to evaluate the bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer. Based on the proven effect of bone protection during adjuvant endocrine therapy, new treatment guidelines recommend the routine use of bisphosphonates to prevent bone loss during adjuvant therapy, which may likely become the standard practice.
Medical subject headings
- Bisphosphonate-Associated Osteonecrosis of the Jaw
- Bone Density Conservation Agents
- Bone Neoplasms
- Breast Neoplasms
- Diphosphonates